Measuring pharmacogenetics in special groups: Geriatrics

Davide Seripa, Francesco Panza, Julia Daragjati, Giulia Paroni, Alberto Pilotto

Research output: Contribution to journalArticle

Abstract

Introduction: The cytochrome P450 (CYP) enzymes oxidize about 80% of the most commonly used drugs. Older patients form a very interesting clinical group in which an increased prevalence of adverse drug reactions (ADRs) and therapeutic failures (TFs) is observed. Might CYP drug metabolism change with age, and justify the differences in drug response observed in a geriatric setting?Areas covered: A complete overview of the CYP pharmacogenetics with a focus on the epigenetic CYP gene regulation by DNA methylation in the context of advancing age, in which DNA methylation might change.Expert opinion: Responder phenotypes consist of a continuum spanning from ADRs to TFs, with the best responders at the midpoint. CYP genetics is the basis of this continuum on which environmental and physiological factors act, modeling the phenotype observed in clinical practice. Physiological age-related changes in DNA methylation, the main epigenetic mechanisms regulating gene expression in humans, results in a physiological decrease in CYP gene expression with advancing age. This may be one of the physiological changes that, together with increased drug use, contributed to the higher prevalence of ADRs and TFs observed in the geriatric setting, thus, making geriatrics a special group for pharmacogenetics.

Original languageEnglish
Pages (from-to)1073-1088
Number of pages16
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume11
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Geriatrics
Pharmacogenetics
Cytochrome P-450 Enzyme System
Pharmaceutical Preparations
DNA Methylation
Drug-Related Side Effects and Adverse Reactions
Gene expression
Epigenomics
Phenotype
Gene Expression
Expert Testimony
Metabolism
Therapeutics

Keywords

  • CYP
  • DNA methylation
  • Epigenetics
  • Geriatrics
  • Pharmacogenetics

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Medicine(all)

Cite this

Measuring pharmacogenetics in special groups : Geriatrics. / Seripa, Davide; Panza, Francesco; Daragjati, Julia; Paroni, Giulia; Pilotto, Alberto.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 11, No. 7, 01.07.2015, p. 1073-1088.

Research output: Contribution to journalArticle

Seripa, Davide ; Panza, Francesco ; Daragjati, Julia ; Paroni, Giulia ; Pilotto, Alberto. / Measuring pharmacogenetics in special groups : Geriatrics. In: Expert Opinion on Drug Metabolism and Toxicology. 2015 ; Vol. 11, No. 7. pp. 1073-1088.
@article{82481083fb7a4484899bf76120e0ea7f,
title = "Measuring pharmacogenetics in special groups: Geriatrics",
abstract = "Introduction: The cytochrome P450 (CYP) enzymes oxidize about 80{\%} of the most commonly used drugs. Older patients form a very interesting clinical group in which an increased prevalence of adverse drug reactions (ADRs) and therapeutic failures (TFs) is observed. Might CYP drug metabolism change with age, and justify the differences in drug response observed in a geriatric setting?Areas covered: A complete overview of the CYP pharmacogenetics with a focus on the epigenetic CYP gene regulation by DNA methylation in the context of advancing age, in which DNA methylation might change.Expert opinion: Responder phenotypes consist of a continuum spanning from ADRs to TFs, with the best responders at the midpoint. CYP genetics is the basis of this continuum on which environmental and physiological factors act, modeling the phenotype observed in clinical practice. Physiological age-related changes in DNA methylation, the main epigenetic mechanisms regulating gene expression in humans, results in a physiological decrease in CYP gene expression with advancing age. This may be one of the physiological changes that, together with increased drug use, contributed to the higher prevalence of ADRs and TFs observed in the geriatric setting, thus, making geriatrics a special group for pharmacogenetics.",
keywords = "CYP, DNA methylation, Epigenetics, Geriatrics, Pharmacogenetics",
author = "Davide Seripa and Francesco Panza and Julia Daragjati and Giulia Paroni and Alberto Pilotto",
year = "2015",
month = "7",
day = "1",
doi = "10.1517/17425255.2015.1041919",
language = "English",
volume = "11",
pages = "1073--1088",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Measuring pharmacogenetics in special groups

T2 - Geriatrics

AU - Seripa, Davide

AU - Panza, Francesco

AU - Daragjati, Julia

AU - Paroni, Giulia

AU - Pilotto, Alberto

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Introduction: The cytochrome P450 (CYP) enzymes oxidize about 80% of the most commonly used drugs. Older patients form a very interesting clinical group in which an increased prevalence of adverse drug reactions (ADRs) and therapeutic failures (TFs) is observed. Might CYP drug metabolism change with age, and justify the differences in drug response observed in a geriatric setting?Areas covered: A complete overview of the CYP pharmacogenetics with a focus on the epigenetic CYP gene regulation by DNA methylation in the context of advancing age, in which DNA methylation might change.Expert opinion: Responder phenotypes consist of a continuum spanning from ADRs to TFs, with the best responders at the midpoint. CYP genetics is the basis of this continuum on which environmental and physiological factors act, modeling the phenotype observed in clinical practice. Physiological age-related changes in DNA methylation, the main epigenetic mechanisms regulating gene expression in humans, results in a physiological decrease in CYP gene expression with advancing age. This may be one of the physiological changes that, together with increased drug use, contributed to the higher prevalence of ADRs and TFs observed in the geriatric setting, thus, making geriatrics a special group for pharmacogenetics.

AB - Introduction: The cytochrome P450 (CYP) enzymes oxidize about 80% of the most commonly used drugs. Older patients form a very interesting clinical group in which an increased prevalence of adverse drug reactions (ADRs) and therapeutic failures (TFs) is observed. Might CYP drug metabolism change with age, and justify the differences in drug response observed in a geriatric setting?Areas covered: A complete overview of the CYP pharmacogenetics with a focus on the epigenetic CYP gene regulation by DNA methylation in the context of advancing age, in which DNA methylation might change.Expert opinion: Responder phenotypes consist of a continuum spanning from ADRs to TFs, with the best responders at the midpoint. CYP genetics is the basis of this continuum on which environmental and physiological factors act, modeling the phenotype observed in clinical practice. Physiological age-related changes in DNA methylation, the main epigenetic mechanisms regulating gene expression in humans, results in a physiological decrease in CYP gene expression with advancing age. This may be one of the physiological changes that, together with increased drug use, contributed to the higher prevalence of ADRs and TFs observed in the geriatric setting, thus, making geriatrics a special group for pharmacogenetics.

KW - CYP

KW - DNA methylation

KW - Epigenetics

KW - Geriatrics

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=84931051597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931051597&partnerID=8YFLogxK

U2 - 10.1517/17425255.2015.1041919

DO - 10.1517/17425255.2015.1041919

M3 - Article

C2 - 25990744

AN - SCOPUS:84931051597

VL - 11

SP - 1073

EP - 1088

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 7

ER -